Regulatory T cell-directed therapy for graft-versus-host disease

The use of adoptively-transferred regulatory T cell (Tregs) for the treatment of graft-versus-host disease (GVHD) is limited by lack of clinically-applicable cell manufacturing methods. This study presents a good-manufacturing-practice compliant platform for the isolation, purification, expansion and gene-marking of Tregs, overcoming the current challenges associated with Treg-directed therapy for clinical use. This research provides a platform for future phase 1 clinical trials using gene-marked Tregs that can be tracked in vivo, which represents an important step forward in addressing the clinical and translational need in Treg-directed therapies